Corbus Pharmaceuticals Holdings Inc

NASDAQ:CRBP   3:59:51 PM EDT
1.41
+0.04 (+2.92%)
Products, Regulatory

Corbus Pharmaceuticals Announces Topline Results From Determine Phase 3 Study Of Lenabasum For Treatment Of Dermatomyositis

Published: 06/24/2021 12:16 GMT
Corbus Pharmaceuticals Holdings Inc (CRBP) - Corbus Pharmaceuticals Announces Topline Results From Determine Phase 3 Study of Lenabasum for Treatment of Dermatomyositis.
Corbus Pharmaceuticals Holdings Inc - Study Did Not Meet Primary Endpoint of Total Improvement Score (tis) at Week 28.
Corbus Pharmaceuticals - Additional Findings Included Nominally Significant Improvements in Tis and Cdasi Depending on Dermatomyositis Subtype.
Corbus Pharmaceuticals - Lenabasum Treatment Was Safe and Well-tolerated in Study.